Sunshine Biopharma (SBFM)
Market Price (12/18/2025): $1.4 | Market Cap: $6.4 MilSector: Health Care | Industry: Pharmaceuticals
Sunshine Biopharma (SBFM)
Market Price (12/18/2025): $1.4Market Cap: $6.4 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -143%, 3Y Excs Rtn is -168% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22% | ||
| Key risksSBFM key risks include [1] a history of unprofitability and reliance on potentially dilutive financing, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -143%, 3Y Excs Rtn is -168% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22% |
| Key risksSBFM key risks include [1] a history of unprofitability and reliance on potentially dilutive financing, Show more. |
Valuation, Metrics & Events
SBFM Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
1. Expanded Net Loss in Q2 2025 Earnings: Sunshine Biopharma reported its fiscal Q2 2025 earnings on August 12, 2025, revealing a significant expansion in net loss to $1.77 million, a 258.3% increase compared to the previous year. Although earnings per share improved, the widened net loss contributed to investor skepticism, with the stock declining in the post-earnings period and losing 7.79% month-to-date in August 2025.
2. Continued Unprofitability Forecast: Analysts project that Sunshine Biopharma will remain unprofitable over the next three years. This ongoing forecast of unprofitability creates persistent investor uncertainty and can exert downward pressure on the stock price.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SBFM Return | 233% | 0% | 42567% | -58% | -99% | -54% | 53% |
| Peers Return | � | � | -72% | -35% | -47% | -50% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 14% | 108% |
Monthly Win Rates [3] | |||||||
| SBFM Win Rate | 17% | 0% | 42% | 17% | 33% | 33% | |
| Peers Win Rate | � | � | 28% | 40% | 33% | 30% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| SBFM Max Drawdown | -78% | 0% | 0% | -63% | -100% | -59% | |
| Peers Max Drawdown | � | � | -77% | -70% | -64% | -54% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: APRE, ENSC, SCYX, CING, BRTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)
How Low Can It Go
| Event | SBFM | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.5% | -25.4% |
| % Gain to Breakeven | 3954.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -80.0% | -33.9% |
| % Gain to Breakeven | 400.0% | 51.3% |
| Time to Breakeven | 73 days | 148 days |
Compare to LLY, JNJ, MRK, PFE, BMY
In The Past
Sunshine Biopharma's stock fell -97.5% during the 2022 Inflation Shock from a high on 4/7/2022. A -97.5% loss requires a 3954.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Trade Ideas
Select past ideas related to SBFM. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.8% | 16.8% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.4% | -6.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 5.2% | 5.2% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.4% | 3.4% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 14.4% | 14.4% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.8% | 16.8% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.4% | -6.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 5.2% | 5.2% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.4% | 3.4% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 14.4% | 14.4% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Sunshine Biopharma
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.11 |
| Mkt Cap | 0.0 |
| Rev LTM | 0 |
| Op Inc LTM | -14 |
| FCF LTM | -12 |
| FCF 3Y Avg | -10 |
| CFO LTM | -12 |
| CFO 3Y Avg | -9 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.7% |
| Rev Chg 3Y Avg | 1,001.2% |
| Rev Chg Q | -49.4% |
| QoQ Delta Rev Chg LTM | -10.0% |
| Op Mgn LTM | -1,181.1% |
| Op Mgn 3Y Avg | -578.6% |
| QoQ Delta Op Mgn LTM | -59.4% |
| CFO/Rev LTM | -1,145.7% |
| CFO/Rev 3Y Avg | -455.8% |
| FCF/Rev LTM | -1,145.7% |
| FCF/Rev 3Y Avg | -455.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | 13.1 |
| P/EBIT | -0.7 |
| P/E | -0.9 |
| P/CFO | -0.9 |
| Total Yield | -114.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -132.8% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -10.2% |
| 3M Rtn | -29.7% |
| 6M Rtn | -25.3% |
| 12M Rtn | -46.3% |
| 3Y Rtn | -92.1% |
| 1M Excs Rtn | -11.0% |
| 3M Excs Rtn | -33.1% |
| 6M Excs Rtn | -37.7% |
| 12M Excs Rtn | -58.2% |
| 3Y Excs Rtn | -162.5% |
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/2/2025 | 8.2% | -31.2% | -32.2% |
| 11/7/2024 | -1.1% | -5.5% | 9.6% |
| 8/19/2024 | -3.6% | -5.2% | -3.2% |
| 4/1/2024 | 76.0% | 68.6% | -85.8% |
| 11/13/2023 | -12.1% | -8.3% | -10.0% |
| 8/11/2023 | 0.0% | -9.2% | -26.5% |
| 5/11/2023 | -18.8% | -29.7% | -37.5% |
| SUMMARY STATS | |||
| # Positive | 3 | 1 | 1 |
| # Negative | 4 | 6 | 6 |
| Median Positive | 8.2% | 68.6% | 9.6% |
| Median Negative | -7.8% | -8.8% | -29.3% |
| Max Positive | 76.0% | 68.6% | 9.6% |
| Max Negative | -18.8% | -31.2% | -85.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11132025 | 10-Q 9/30/2025 |
| 6302025 | 8122025 | 10-Q 6/30/2025 |
| 3312025 | 5152025 | 10-Q 3/31/2025 |
| 12312024 | 4012025 | 10-K 12/31/2024 |
| 9302024 | 11052024 | 10-Q 9/30/2024 |
| 6302024 | 8162024 | 10-Q 6/30/2024 |
| 3312024 | 5202024 | 10-Q 3/31/2024 |
| 12312023 | 3282024 | 10-K 12/31/2023 |
| 9302023 | 11132023 | 10-Q 9/30/2023 |
| 6302023 | 8102023 | 10-Q 6/30/2023 |
| 3312023 | 5102023 | 10-Q 3/31/2023 |
| 12312022 | 4042023 | 10-K 12/31/2022 |
| 9302022 | 11072022 | 10-Q 9/30/2022 |
| 6302022 | 8032022 | 10-Q 6/30/2022 |
| 3312022 | 5062022 | 10-Q 3/31/2022 |
| 12312021 | 3212022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |